Selective elimination of leukemia stem cells: hitting a moving target.
about
Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunitiesOn the origin and destination of cancer stem cells: a conceptual evaluationSustained proliferation in cancer: Mechanisms and novel therapeutic targetsNovel Acylguanidine Derivatives Targeting Smoothened Induce Antiproliferative and Pro-Apoptotic Effects in Chronic Myeloid Leukemia CellsLASP1 is a novel BCR-ABL substrate and a phosphorylation-dependent binding partner of CRKL in chronic myeloid leukemiaDifferentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.Selenium suppresses leukemia through the action of endogenous eicosanoids.IGF-IR determines the fates of BCR/ABL leukemia.Chemopreventive Effects of Dietary Eicosapentaenoic Acid Supplementation in Experimental Myeloid Leukemia.Resveratrol downregulates interleukin-6-stimulated sonic hedgehog signaling in human acute myeloid leukemia.Next-generation medicine: combining BCR-ABL and Hedgehog-targeted therapies.Sirtuins, tissue maintenance, and tumorigenesis.Depletion of γ-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with ImatinibTargeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.Issues in current management of chronic myeloid leukemia: Importance of molecular monitoring on long term outcomeProperties and feasibility of using cancer stem cells in clinical cancer treatment.G0S2 inhibits the proliferation of K562 cells by interacting with nucleolin in the cytosol.Antineoplastic effects and mechanisms of micheliolide in acute myelogenous leukemia stem cells.The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment.Chronic myeloid leukemia: overview of new agents and comparative analysis.Genetic events other than BCR-ABL1.The cancer stem cell hypothesis: a guide to potential molecular targets.Regulatory effect of chemokines in bone marrow niche.Update on emerging treatments for chronic myeloid leukemia.Selective surface marker and miRNA profiles of CD34+ blast-derived microvesicles in chronic myelogenous leukemiaNovel drug therapies in myeloid leukemia.Novel signaling axis in CML-initiating cells.Synthesis and antileukemic activities of C1-C10-modified parthenolide analogues.Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia.RNA editing-dependent epitranscriptome diversity in cancer stem cells.Oroxyloside A Overcomes Bone Marrow Microenvironment-Mediated Chronic Myelogenous Leukemia Resistance to Imatinib via Suppressing Hedgehog Pathway.The human Smoothened inhibitor PF-04449913 induces exit from quiescence and loss of multipotent Drosophila hematopoietic progenitor cells.Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2.Cross talk between Wnt/β-catenin and Irf8 in leukemia progression and drug resistance.Analysis of MicroRNA-Mediated Translation Activation of In Vitro Transcribed Reporters in Quiescent Cells.Targeting cancer stem cells and signaling pathways by resveratrol and pterostilbene.Characteristics of doxorubicin-selected multidrug-resistant human leukemia HL-60 cells with tolerance to arsenic trioxide and contribution of leukemia stem cells.Modulation of leukotriene signaling inhibiting cell growth in chronic myeloid leukemia.
P2860
Q28071384-E5673559-2219-4395-A4C8-4E83F0A2C01DQ28284488-864FD11C-E09E-4AAB-A9D7-841122E659B1Q28396388-4394B0A8-BC9D-41B0-9A07-30720EE61989Q28550487-4D2757C1-2AB7-40B6-A191-8626FFA0C3C1Q30009399-09D43DD2-76F6-410B-A9EE-403D7B6830F6Q33618407-1313C4A9-282C-4B7C-8057-94BB839A2327Q33916841-30A810AB-15B5-48E9-905B-F2B72F34F802Q35061363-323E1E99-BF78-4560-A4BC-E23BF150CC46Q36132830-6ADA03E3-34B0-4C74-94CE-67BAA699AD5AQ36663757-96EDDA7A-AAB1-4B3B-8C40-3566E6328A72Q36699009-D3688364-AADE-4B2A-BCD8-704F682E1FD1Q37150507-A0B62C89-C5FB-4D8D-94BE-EA7D8FECAC42Q37202328-BDDB70F2-39A1-4783-A7A7-8E3CA6946046Q37395704-134CF000-D008-43CF-B47C-FC345638D6DCQ37422287-C02B3026-25DD-4BC7-9336-3A9A13542EAFQ37596687-9F2FD52E-AD26-416A-A9EA-2ADAA92D20BFQ37625352-98A22488-C853-4D1B-A61A-6A3DFBAD577FQ37662181-0402F828-263B-4221-B087-8D4E90FA4BB9Q37727786-A7EFB450-B151-4F92-A107-E2556BCCC8FBQ38097728-6C2989D0-BD08-4828-982D-303899BB7B37Q38177162-A0D29423-C13D-45FF-8292-6B46DD89454EQ38254181-2240EC37-1072-4966-A0E1-8915614F8CD4Q38365227-884AE737-FDFA-49F2-B79C-74CD2442FA87Q38397515-25A889DC-A4C0-40AE-9B61-0C58B877EE3CQ38430207-0443645F-1E4E-4D04-84C1-184B9B3B1158Q38510486-D937188B-CE33-44C3-A051-1EBEB1DEC1DCQ38817081-88451ED8-7C47-45EE-96AE-89BEDB9F71E1Q38862410-AE2A0540-2948-4752-8CB2-FB167F9AE520Q38943340-0757F7BC-D8EB-48F3-A2D7-36FB44012C64Q39247132-3228FDC7-A74D-4B5E-8EC7-E54650C1D405Q41370892-DDA10C29-3180-49C8-BE02-48E660FE7B61Q42125187-90DBA5FE-CE70-4A72-A391-B94776DEDF3CQ42316726-73A684F8-E5BE-44DB-92A3-80332B826F79Q42938924-9DA63E5A-F710-40FD-B220-9E93B8FDDF45Q47654557-11949022-25A7-4CA1-92AF-C4B8EF95D125Q48179398-BBD627AC-2FEB-40A3-B12D-75DB32D20F18Q49334989-F6685F46-8F6F-4801-BC83-535965918A72Q51279012-5B5A435A-0F05-4A57-B9B4-E4CB27BCAACE
P2860
Selective elimination of leukemia stem cells: hitting a moving target.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Selective elimination of leukemia stem cells: hitting a moving target.
@en
type
label
Selective elimination of leukemia stem cells: hitting a moving target.
@en
prefLabel
Selective elimination of leukemia stem cells: hitting a moving target.
@en
P1433
P1476
Selective elimination of leukemia stem cells: hitting a moving target.
@en
P2093
Catriona H M Jamieson
P356
10.1016/J.CANLET.2012.08.006
P407
P50
P577
2012-08-17T00:00:00Z